Key Takeaways
- •A national registration is a real regulatory fact and not a universal one. Semax being on Russia's essential medicines list tells you a Russian regulator reviewed something. It does not transfer.
- •Volume of publication is not weight of evidence. Hundreds of papers from one research tradition can carry less evidential weight than three independent replications.
- •The question to ask is not "how many studies" but "how many independent sources". Those are different numbers and only the second one matters.
- •Language is a real barrier and not a reason for dismissal. Work published in Russian is not thereby wrong, it is thereby harder for most readers to check, which is a different problem requiring a different response.
- •Absence of Western trials is weak evidence, and its direction is not obvious. It reflects commercial and regulatory incentives at least as much as it reflects scientific merit.
- •The honest position on all three compounds is under-determined, and a supplier claiming otherwise in either direction is telling you about their incentives.
Semax sits on the Russian Federation's List of Vital and Essential Drugs, added by government order on 7 December 2011. It is stocked in Russian pharmacies. It has also never been evaluated, approved or marketed in most other countries, and it holds no approval from the FDA.
Both of those are true. Nearly every Western write-up picks one and builds a case on it. The pro-Semax version cites the Russian registration as regulatory validation. The dismissive version cites the absence of a US approval as proof the compound does nothing. Neither has engaged with the actual difficulty, which is that the evidence exists, and most readers cannot assess it.
Volta does not sell Semax, Selank or epithalon. That makes this the easiest article in this series to write honestly, and worth saying plainly: there is nothing at the end of it for us to sell you. What there is instead is a method for judging any body of research you cannot independently verify, which turns out to be a more useful thing to own than an opinion about three peptides.
The three compounds
| Compound | Sequence | Derived from | Origin | Regulatory position |
|---|---|---|---|---|
| Semax | Met-Glu-His-Phe-Pro-Gly-Pro | ACTH(4-10) fragment analogue | Institute of Molecular Genetics, Russian Academy of Sciences, Moscow | On Russia's List of Vital and Essential Drugs since 7 December 2011. No US approval; unscheduled. Not evaluated or marketed in most countries |
| Selank | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Synthetic analogue of tuftsin | Institute of Molecular Genetics, Russian Academy of Sciences | Available in Russian and Ukrainian pharmacies. No Western approval |
| Epithalon | Ala-Glu-Asp-Gly | Synthetic tetrapeptide, pineal-derived bioregulator tradition | Associated with the St Petersburg Institute of Bioregulation and Gerontology | No approval in any Western jurisdiction |
All three share a shape: developed inside one national research system, studied extensively within it, and largely unexamined outside it.
Why "hundreds of studies" is the wrong count
The instinct when assessing a compound is to count papers. It is the wrong instinct, and here is why.
Evidence gains strength from independence, not from repetition. Two laboratories with different funding, different reagent suppliers, different analytical platforms and different reputational stakes, arriving at the same result, is a genuinely strong signal. The same laboratory publishing the same finding thirty times is one result and twenty-nine restatements.
So the number that matters is not how many papers exist but how many independent lines of evidence exist. A literature can be enormous and, in this specific sense, thin. It can also be small and robust: three papers from three unconnected groups is a stronger position than three hundred from one.
This is not a criticism unique to Russian peptide research. It is the same structure that produces the replication problems in Western psychology and preclinical oncology, and it is exactly the failure mode behind the BPC-157 literature, which is large, interesting and heavily concentrated in a small number of collaborating groups.
The practical form of the question:
If the single most prolific group working on this compound turned out to be wrong, how much of the case would survive?
If the answer is "very little", the evidence base is a single point of failure regardless of its size.
Five tests for a literature you cannot read
None of these require the source language. All of them are things you can do from an abstract database in an afternoon.
1. Count author clusters, not papers. Pull the author lists from the twenty most-cited papers on the compound. How many genuinely separate groups appear? Shared senior authors, shared institutions and shared funders collapse into one cluster. This single count usually settles the question.
2. Look for a hostile replication. Findings that survive attempts to knock them down are worth more than findings nobody tried. A literature containing no failed replications is not a literature where nothing failed; it is usually a literature where nobody outside tried, or where null results were not published.
3. Check whether the compound travelled. Genuinely robust and commercially interesting findings tend to get licensed, partnered or copied. Decades of registered use in one market with no attempt to enter others is a fact worth explaining, and the explanations are not all scientific: patent life, market size, the expense of a Western regulatory package and geopolitical friction are all real. It is a signal, not a verdict.
4. Read the methods sections that are translated. Abstracts are indexed in English far more often than full texts. Sample size, randomisation, blinding and control arms are usually recoverable from an abstract. Small, unblinded, uncontrolled studies are weak evidence in any language.
5. Separate the mechanism from the outcome. Mechanistic work travels better across a language barrier, because a Western group measuring the same receptor binding will get the same answer or will not. Outcome claims in people are much harder to check. A compound can have well-replicated mechanistic data and completely unverified clinical claims, and the two get quoted as if they were one body of support.
What the tests give you here
Applied to these three compounds, honestly:
| Test | What it shows |
|---|---|
| Independent author clusters | Concentrated. The research is dominated by the originating institutions and their collaborators, most heavily so for epithalon |
| Hostile replication | Sparse. Western groups have largely not engaged, in either direction |
| Did it travel | Semax and Selank remain regionally registered after decades. No major Western development programme followed |
| Recoverable methods | Mixed. Some well-described studies, many small and without modern trial reporting standards |
| Mechanism vs outcome | Semax has the strongest position: independent mechanistic work exists, including studies on BDNF and TrkB signalling in rodent models. Outcome claims are far less verified |
The conclusion that follows is genuinely a shrug, and a shrug is the correct answer when it is the correct answer. These compounds are neither established nor debunked. They occupy the honest category of "studied, in one place, to a standard that makes external assessment hard", and there is no amount of confident writing on either side that changes that.
Anyone who tells you Semax is proven is over-reading a regional registration. Anyone who tells you it is snake oil is treating the absence of Western interest as evidence, which it is not. Both are more comfortable positions than the accurate one.
What would actually change the picture
Worth naming, because it makes the current position concrete:
- A pre-registered trial run by a group with no connection to the originating institutes, reported to modern standards.
- A failed independent replication of a central mechanistic claim, which would be informative in the other direction and is equally absent.
- A systematic review with full-text translation rather than abstract-level inclusion, which is expensive and rare and is the single highest-value thing anyone could do here.
Until one of those arrives, the position does not move, and a vendor page that has moved it has done so without new evidence.
Why this method is the point
The three compounds are the example. The method is the deliverable, and it transfers.
Every compound in this market has a literature with a shape: how many independent groups, how much hostile scrutiny, whether findings travelled, how recoverable the methods are, and whether mechanism and outcome are being conflated. Running those five checks takes an afternoon and it is the difference between having read about a compound and having assessed it.
It also protects against the failure mode that a research-use market runs on, which is a large volume of confident secondary writing built on a small volume of primary work. The evidence grade tool applies a similar scoring, what the human evidence actually shows maps where the compounds we do sell actually sit, and why two trials of the same drug give different numbers covers the arithmetic traps in trials you can read.
Frequently Asked Questions
Is Semax approved anywhere?
Yes, in Russia, where it has been on the government's List of Vital and Essential Drugs since a 7 December 2011 order and is dispensed through pharmacies. It carries no approval in the United States, the European Union or Canada, and has not been evaluated by those regulators. A registration in one jurisdiction is a real regulatory fact that does not transfer to others.
Does Russian-language publication make research less reliable?
No. It makes it less checkable by readers who do not read Russian, which is a separate problem. The reliability question turns on study design, independence and replication, exactly as it does in English. The practical consequence is that a reader has to lean harder on abstract-level method details and on author-cluster analysis rather than on close reading.
Why have Western companies not developed these compounds?
Several reasons that have nothing to do with efficacy, including expired or unavailable patent protection, the cost of a full Western regulatory package, uncertain market size, and geopolitical and commercial friction. Scientific doubt is also a possible reason. Because the explanations are not separable from outside, absence of Western development is a weak signal rather than a verdict.
Is epithalon's telomerase evidence solid?
It is concentrated. The bulk of the work traces back to one research tradition, and independent verification from unconnected laboratories is limited. That does not make the findings wrong. It does mean the evidence base has a single point of failure, and the appropriate confidence is lower than the paper count suggests.
How many independent groups should I want to see?
There is no threshold that turns uncertainty into certainty, but the shape of the answer matters more than the number. One group is a hypothesis. Two unconnected groups agreeing is meaningfully stronger. Three or more, including at least one that tried to find a problem, is a finding you can build on.
Does Volta sell these compounds?
No. Semax, Selank and epithalon are not in our catalogue, which is why this article has no product recommendation attached to it. The method it describes is aimed at compounds we do sell as much as at ones we do not, and it produces uncomfortable answers about several of them.
